Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227.
DGX or PNTG: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks?
US lab operator Quest Diagnostics to launch bird flu test at end of October
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.
Overlooked Stock: DGX
One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.
Quest Diagnostics (DGX) Q3 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Michael Cherny - Leerink Partners Patrick Donnelly - Citi Pito Chickering - Deutsche Bank Meghan Holtz - Jefferies David Westenberg - Piper Sandler Jack Meehan - Nephron Research Elizabeth Anderson - Evercore ISI Erin Wright - Morgan Stanley Stephanie Davis - Barclays Lisa Gill - JP Morgan Andrew Brackmann - William Blair Kevin Caliendo - UBS Michael Riskin - Bank of America Operator Welcome to the Quest Diagnostics Third Quarter 2024 conference call. At the request of the company, this call is being recorded.
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics Inc DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics (DGX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging populations and preventive medical testing, promising 10% annual returns and 6-8% annual dividend growth. DGX's financials have stabilized post-Covid, with revenue, earnings, and free cash flow rising, supported by share buybacks and strategic acquisitions.
